Oxcarbazepine (All indications) updated on 04-22-2025

Amniotic fluid problems (polyhydramnios and/or oligohydramnios)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S9039
R30847		 Aydin (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2020 Amniotic fluid problems (polyhydramnios/oligohydramnios) throughout pregnancy retrospective cohort exposed to other treatment, sick excluded Adjustment: No 1.86 [0.03;115.45] C
excluded (control group) 		0/4   0/7 0 4
ref
S9040
R30857		 Aydin (Oxcarbazepine) (Controls unexposed, sick), 2020 Amniotic fluid problems (polyhydramnios/oligohydramnios) throughout pregnancy retrospective cohort unexposed, sick Adjustment: No 6.14 [0.10;363.16] C 0/4   0/22 0 4
ref
Total 1 studies 6.14 [0.10;363.16] 0 4
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Aydin (Oxcarbazepine) (Controls unexposed, sick), 2020Aydin, 2020 1 6.14[0.10; 363.16]040%ROB confusion: criticalROB selection: criticalROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate0.920.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Oxcarbazepine) (Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 6.14[0.10; 363.16]-4 -NAAydin (Oxcarbazepine) (Controls unexposed, sick), 2020 1 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 6.14[0.10; 363.16]-4 -NAAydin (Oxcarbazepine) (Controls unexposed, sick), 2020 1 Tags Adjustment   - No  - No 6.14[0.10; 363.16]-4 -NAAydin (Oxcarbazepine) (Controls unexposed, sick), 2020 1 All studiesAll studies 6.14[0.10; 363.16]-4 -NAAydin (Oxcarbazepine) (Controls unexposed, sick), 2020 10.520.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 9039

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 6.14[0.10; 363.16]-4 -NAAydin (Oxcarbazepine) (Controls unexposed, sick), 2020 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.86[0.03; 115.45]-4 -NAAydin (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2020 10.510.01.0